Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.Redmile Group reported a purchase of 16,317 shares of Krystal Biotech (KRYS 0.33%) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly average pricing.What happenedAccording to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Redmile Group increased its position in Krystal Biotech by 16 ...